

Minutes of Annual General Meeting of Shareholders for the year 2024

of

DOD Biotech Public Company Limited

The Annual General Meeting of Shareholders for the year 2024 held on Thursday 25 April 2024 at 14:00 hrs. This meeting was streamed live via electronic means from DOD Biotech Public Company Limited's room No.111, Moo 2, Tha Chin Sub-district, Mueang Samutsakhon District, Samut Sakhon 74000,

The meeting started at 14.00 hours.

Mrs. Arpaporn Kosolkul, The Company's Chairman and Chairman of the meeting and there were Directors and the Company's Auditor who participated in the meeting as follows:

The Company's Directors who participated in the meeting

1.	Mrs. Arpaporn Kosolkul	Chairman, Member of the Audit Committee and
		Member of the Nomination and Remuneration Committee
2.	Mr. Dusit Chongsutthanamanee	Vice Chairman, Chairman of the Audit Committee, and
		Chairman of the Nomination and Remuneration Committee
3.	Mr. Pongthep Thitapan	Independent Director, Member of the Audit Committee, and
		Member of the Nomination and Remuneration Committee
4.	Mr. Torlarp Chaiyachow	Director and Acting Chief Executive Officer
5.	Ms. Suwarin Konthong	Director and Chief Financial Officer

The Company Secretary

1. Ms. Arachaporn Boonkerd

The Company's auditors from EY Office Company Limited

- 1. Ms. Sumesa Tangyoosuk
- 2. Mrs. Phunnard Phaochajean

Mrs. Arpaporn Kosolkul, The Company's Chairman and Chairman of the meeting, welcomed all shareholders who participated in the Annual General Meeting of Shareholders for the year 2024 and informed the meeting about the Company's information as of March 8, 2024 as follows:

Page 1 / 14



1.	Registered capital	343,471,560.50	Baht
2.	Paid-up Capital	225,207,142.50	Baht
3.	Par value per share	0.50	Baht

The Company specified the list of shareholders who had the right to attend the Annual General Meeting of Shareholders for the year 2024 on the date of 8th March 2024, following the Section 103 of the Public Limited Companies Act B.E. 2535 and Article No.40 of the Articles of Association of the Company states in the shareholders' meeting, the number of the shareholders and proxies (if any) present shall not be less than 25 people and the aggregate number of shares shall not be less than one-third of the paid-up shares, to constitute a quorum.

• The number of shareholders present at the Meeting and proxies in total 29 shareholders who held 153,053,902 shares. The total shares accounted for 33.9806% percent of the Company's 450,414,285 paid-up shares, thus constituting a quorum under clause no. 40 of the Articles of Association.

The Chairman opened the Annual General Meeting of Shareholders for the year 2024 and invited Ms. Arachaporn Boonkerd, Company Secretary, to explain the rules of practice and procedure in the Meeting as follows:

Company Secretary explain the rules of practice and procedure in the Meeting that had been conducted as agendas which were shown on the notice of the Annual General Meeting for the year 2024, every shareholder has one vote per share. The Meeting had 8 agendas, and each agenda has to be voted as follows:

- The Agenda no. 2, Agenda no. 4, Agenda no. 5 and Agenda no. 7 shall have the majority of votes from shareholders present at the meeting. If there is an equal vote, the Chairman shall cast one additional vote as the final vote.
- The Agenda no. 1 and Agenda no. 3 do not require casting votes because this is informative agenda.
- The Agenda No. 6 shall receive a vote of not less than two-thirds of the total number of votes and exclude the votes of the directors who are stakeholders in the amount of 473,100 votes.
- The Agenda No. 8 is the accepting agenda proposed by shareholders.

Company Secretary informed the meeting that this Annual General Meeting of Shareholders, DOD Biotech Public Company Limited shall keep, use and disclose personal information, audios, and videos of all attendants for recording and preparing the minutes of the Meeting, organizing the Meeting etc. All shareholders could read the additional details related to the Personal Data Protection as indicated in the enclosure of the Meeting's invitation letter and on the Company's website.



Moreover, before casting votes on each agenda, the attendees of the Meeting shall have an opportunity to ask or express their opinions in involving agenda as appropriate. The shareholders who intend to ask or express their opinions are required to inform their name and last name to the Meeting every time. Since this meeting is held through electronic means, there are **rules**, **voting methods**, **vote counting**, and method to ask questions or express opinions as follows:

- The meeting will consider the matters in order of the agenda specified in the invitation letter. By presenting information for each agenda, the Company will give shareholders an opportunity to ask questions before voting and will notify the result of the vote at the meeting when the votes are counted.
- 2. For voting, choose the agenda then press the "Vote" button, the system will display a button for voting, a total of 3 buttons which is 1. Agree (Green) 2. Disagree (Red) 3. Abstain (Orange). For shareholder who has more than one proxies, the system will display all names of proxies then shareholder can vote separately for each user account.

For Cancel the vote, press the "Cancel Vote" button. For any shareholder who has not voted within the specified time. The company will assume that the shareholder agrees with that agenda. The voting can be edited until the voting results are closed. The Company allows two minutes for voting. When the voting results are closed, the result of that agenda will be announced at the meeting.

- 3. In the case of shareholders accepting proxies from many shareholders, press to "Account" button and press on the "Change Account" button to access other shareholders' accounts. The system will not remove votes from the meeting base.
- 4. In case a shareholder wishes to leave the meeting before closing the voting, shareholders' votes will not be counted as a quorum for such agenda, and the votes will not be counted immediately in the remaining agenda. However, leaving the quorum in any agenda will not disqualify the shareholders' rights or proxies to return to the meeting and vote on the next agenda in the system.
- 5. For asking questions or expressing opinions before voting for each agenda, the company will give the attendees an opportunity to ask questions or express opinions on issues related to that agenda. By select the agenda and press "Question" button, then type the question then click "Send". The company will answer questions in the meeting room on the agenda related to that question. The company reserves the right to consider selecting questions as

Page 3 / 14



appropriate. The attendees must inform their first and last names, and status as a shareholder or proxy before asking questions every time. That is for the company to be able to accurately and completely recorded the minutes of the meeting.

However, the company reserves the right to delete any disrespectful comments, defame others, or violate any laws Including infringement of the rights of others, disturbing the meeting, or causing trouble to other attendees.

- 6. In the event that there are a large number of shareholders wishing to ask questions, to maintain the duration of the meeting, let the shareholders ask questions via message for the staff will keep that questions then answer at the end of the meeting or on the company's website.
- 7. In case of shareholders encounter problems entering the meeting system or voting system, please follow the instructions given along with the invitation letter or press "Help" button or contact Inventech Call Center and Line Official Account.
- 8. In case of the system crashes during the meeting, shareholders will receive an email to return to the meeting through the support system.

The Chairman then commenced the Meeting with the following agenda:

Agenda 1 To acknowledge the directors' report on the Company's performance for the year 2023

The Chairman assigned Ms. Suwarin Konthong, Chief Financial Officer to present information to the Meeting.

Chief Financial Officer presented the Company's performance in 2023 to the meeting, a summary of which was as follows:

Revenue Structure

Type of Income	Year 2023		Year 2022		
rype of income	Million Baht %		Million Baht	%	
Sale Revenues					
- Beauty Products	167.48	23.58	359.79	65.62	
- Health Products	510.68	71.92	177.37	32.35	
Total Sales Revenues	678.16	95.50	537.16	97.96	
Others Income	31.94	4.50	11.17	2.04	
Total Income	710.10	100.00	548.33	100.00	



DOD Biotech Public Company Limited

111 Moo 2 Tumbol Thachin, Amphur Muang Samutsakhon Samutsakhon 74000

Income Statement (Consolidated Financial Statement)

(Unit : Million THB)							
	20	023	2022		Increase/((Decrease)	
Revenues from Sale	678.15	100.00%	537.16	100.00%	140.99	26.25%	
Cost of Sales	415.21	61.23%	396.66	73.84%	18.55	4.68%	
Gross Profit	262.94	38.77%	140.50	26.16%	122.44	87.15%	
Selling and Distribution Expenses	84.07	12.40%	16.86	3.14%	67.21	398.64%	
Administrative Expenses	163.96	24.18%	146.20	27.22%	17.76	12.15%	
Operating Profit(Loss)	14.91	2.20%	(22.56)	(4.20%)	37.47	166.09%	
Other Revenues	31.94	4.71%	11.17	2.08%	20.77	185.94%	
Finance Income	0.26	0.04%	0.11	0.02%	0.15	136.36%	
Finance Cost	8.27	1.22%	7.09	1.32%	1.18	16.64%	
Other expenses	(10.04)	(1.48%)	405.86	75.56%	(415.90)	(102.47%	
Profit (loss) before income tax expenses	48.88	7.21%	(424.23)	(78.98%)	473.11	111.52%	
Income tax income (expenses)	(28.06)	(4.14%)	79.11	14.73%	107.17	135.47%	
Profit(Loss) for the year from continued operation	20.82	3.07%	(345.12)	(64.25%)	365.94	106.03%	
Loss for the period from discontinued	(14.45)	(2.13%)	(60.03)	(11.18%)	(45.58)	(75.93%)	
Profit(Loss) for the year	6.37	0.94%	(405.15)	(75.42%)	411.52	101.57%	
Non-controlling interests of the subsidiaries							
Profit(Loss) for the year from continued operation	0.63	0.09%	(2.15)	(0.40%)	2.78	129.30%	
Loss for the year from discontinued operation	(1.44)	(0.21%)	(4.66)	(0.87%)	(3.22)	69.10%	
Profit(Loss) for the year attributable to Non-controlling interest	(0.81)	(0.12%)	(6.81)	(1.27%)	6.00	88.11%	
Profit(Loss) attributable to Equity holders of the parent company	7.18	1.06%	(398.34)	(74.16%)	405.52	101.80%	

					(Unit : N	Aillion THB)
	As at 31 Dec	ember 2023	As at 31 December 2022		Cha	nge
Cash and cash equivalents	67.99	4.66%	30.27	2.34%	37.72	124.61%
Trade and other receivables	111.64	7.66%	57.29	4.44%	54.35	94.87%
Inventories	150.40	10.32%	98.03	7.59%	52.37	53.42%
Other current assets	41.92	2.88%	11.54	0.89%	30.38	263.26%
Total Current Assets	371.95	25.52%	197.13	15.27%	174.82	88.68%
Restricted bank deposits	17.05	1.17%	16.99	1.32%	0.06	0.35%
Other non-current financial assets	2.60	0.18%	2.60	0.20%	-	-
Property, plant and equipment	862.42	59.17%	909.08	70.42%	(46.66)	(5.13%)
Rights of use assets	53.41	3.66%	53.92	4.18%	(0.51)	(0.95%)
Goodwill	0.25	0.02%	-	0.00%	0.25	-
Other intangible assets	50.48	3.46%	5.57	0.43%	44.91	806.28%
Deferred tax assets	90.64	6.22%	92.54	7.17%	(1.90)	(2.05%)
Advance for purchasing fixed assets	8.24	0.57%	12.59	0.98%	(4.35)	(34.55%)
Other non-current assets	0.59	0.04%	0.50	0.04%	0.09	18.00%
Total Non-Current Assets	1,085.68	74.48%	1,093.79	84.73%	(8.11)	(0.74%)
Total Assets	1,457.63	100.00%	1,290.92	100.00%	166.71	12.91%

					(Unit : N	1illion THB)
	As at 31 Dece	As at 31 December 2023 As at 31 December 2022		Cha	inge	
Bank overdrafts and short-term loans from bank	110.49	7.58%	138.70	10.74%	(28.21)	(20.34%)
short-term loan from shareholder	-	0.00%	10.00	0.77%	(10.00)	(100.00%)
Trade and other payables	116.51	7.99%	110.24	8.54%	6.27	5.69%
Current portion of long-term loans	2.12	0.15%	19.81	1.53%	(17.69)	(89.30%)
Current portion of leases liabilities	2.79	0.19%	2.62	0.20%	0.17	6.49%
Income tax payable	21.18	1.45%	1.66	0.13%	19.52	92.16%
Other current liabilities	29.70	2.04%	21.08	1.63%	8.62	40.89%
Total Current Liabilities	282.79	19.40%	304.11	23.56%	(21.32)	(7.01%)
Long-term loans, net of current portion	-	0.00%	2.12	0.16%	(2.12)	(100.00%)
Lease liabilities, net of current portion	53.28	3.66%	55.83	4.32%	(2.55)	(4.57%)
Provision for long-term employee benefits	10.72	0.74%	7.68	0.59%	3.04	39.58%
Deferred tax liabilities	18.49	1.27%	10.68	0.83%	7.81	73.13%
Other non-current liabilities	12.29	0.84%	16.87	1.31%	(4.58)	(27.15%)
Total Non-Current Liabilities	94.78	6.50%	93.18	7.22%	1.60	1.72%
Total Liabilities	377.57	25.90%	397.29	30.78%	(19.72)	(4.96%)
Shareholder's Equity	1,080.06	74.10%	893.63	69.22%	186.43	20.86%
Total Liabilities and Shareholder's Equity	1,457.63	100.00%	1,290.92	100.00%	166.71	12.91%

Page 5/14

```
@dodbiotech
```





For the year of 2023, The Company had the Revenue from Sale of THB 678.15 Million which was increase by THB 140.99 Million or 26.25% compared with the same period of 2022 because the company have changed the customer base for diversified the market risk and revenue increased from its subsidiaries which is distributed owned brands.

The Company had profit (loss) from continued operation amount of THB 20.82 Million, which was increase 106.03% due to the increase of operating profit and decrease of other expenses

For the year of 2023, the Company had loss from discontinued operation by THB 14.45 Million, which decreased compared with the same period of 2022 by THB 60.03 Million due to the two subsidiaries business discontinued operation.

The Company has the profit attributable to equity holders of the parent company by THB 7.18 Million, while in the same period of last year has the loss attributable to equity holders of the parent company by THB (398.34) Million, which was increased THB 405.52 Million or 101.80%, which mainly came from the operating performance improvement and had not impairment loss on financial assets.

As of December 31, 2023, the total assets were increase by THB 166.71 Million or 12.91% compared with December 31, 2022, which mainly came from cash THB 37.72 Million ,the trade and other receivables increased by THB 54.35 million due to the increase of revenue from sale during the period, the inventory was increased by THB 52.37 million, and other intangible assets was increased by THB 44.91 million because of the business acquisition cost that unallocated which arises from the investment in a new subsidiary during the period.

As of December 31, 2023, the total liabilities were decrease by THB 19.72 Million or 4.96% compared with December 31, 2022, which mainly to the decrease of 28.21 million in repayment of bank overdrafts and short-term loans from banks and shareholder's equity increased by THB 186.43 Million or 20.86% because of capital injection from our shareholders.

In conclusion, the restructure of the company and financial structure by raised equity fund is starting to turnaround the Company's operating result in both of operating profit and profit attributable equity holders of the parent company. Additionally, The Company has strategies to increase the potential of the group of companies by investing in the subsidiaries aim to distribute owned brands.



Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

As this agenda item was for acknowledgment the Company's performance for the year 2023, there was no resolution to be adopted.

Agenda 2 To consider approving the Company's audited the financial statements for the year ended December 31, 2023.

The Chairman assigned Ms. Suwarin Konthong, Chief Financial Officer to present information to the Meeting.

Chief Financial Officer presented the Company's performance in 2023 to the meeting, a summary of which was as follows:

Statement of	2023		2022		Change	
Financial Position	Million Baht	%	Million Baht	%	Million Baht	%
Assets	1,457.63	100.00%	1,290.92	100.00%	166.71	12.91%
Liabilities	377.57	25.09%	397.29	30.78%	(19.72)	(4.96%)
Shareholder's Equity	1,080.06	74.10%	893.63	69.22%	186.43	20.86%

Statement of Financial Position (Consolidated financial statements) in Brief

As of December 31, 2023, the total assets were increase by THB 166.71 Million or 12.91% compared with December 31, 2022, which mainly came from cash THB 37.72 Million, the trade and other receivables increased by THB 54.35 million due to the increase of revenue from sale during the period, the inventory was increased by THB 52.37 million, and other intangible assets was increased by THB 44.91 million because of the business acquisition cost that unallocated which arises from the investment in a new subsidiary during the period.

As of December 31, 2023, the total liabilities were decrease by THB 19.72 Million or 4.96% compared with December 31, 2022, which mainly to the decrease of 28.21 million in repayment of bank overdrafts and short-term loans from banks and shareholder's equity increased by THB 186.43 Million or 20.86% because of capital injection from our shareholders.

For the Company's financial position, the Company had current ratio of 1.32 times and debt to equity ratio 0.35 times, showing its sufficient liquidity and strong financial position.



DOD Biotech Public Company Limited

111 Moo 2 Tumbol Thachin, Amphur Muang Samutsakhon Samutsakhon 74000

Income	Statement	(Consolidated)	in	Brief
--------	-----------	----------------	----	-------

ncome Statement (Consolidated) in Brief (Unit : Million TH					
Statement	2022	2021	Change		
Statement	2022	2021	Million Baht	%	
Sales Revenues	678.15	537.16	140.99	26.25%	
Cost of Sale	415.21	396.66	18.55	4.68%	
Gross Profit	262.94	140.50	122.44	87.15%	
Selling Expenses	84.07	16.86	67.21	398.64%	
Administrative Expense	163.96	146.20	17.76	12.15%	
Operating Profit (Loss)	14.91	(22.56)	37.47	166.09%	
Profit (Loss) attributable to shareholders of the parent	7.18	(398.34)	405.52	101.80%	

Major Changes in the Income Statement (consolidated financial statements) as explained in the previous agenda.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

Company Secretary requested shareholders to adopt a resolution approving the Company's audited the financial statements for the year ended December 31, 2023.

The voting results were as follows:

Approved	153,051,902	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Abstained	0	Votes	Equivalent to	0.0000
Total	153,051,902	Votes	Equivalent to	100.0000

The meeting's resolution: With the majority votes of the shareholders who were present at the meeting and casted their votes, the meeting passed the resolution approving the Audited Statement of Financial Position and Income Statement for the year ended 31 December 2023 as proposed in all respects.

Agenda 3 To consider and acknowledge the omission of dividend payments for the year 2023

The Chairman assigned Mr. Dusit Chongsutthanamanee, Vice Chairman to present information to the Meeting.

Page 8 / 14



Vice Chairman presented to the meeting that the dividend policy is to pay a total dividend of not less than 50% of net profits after deductions for tax and the legal reserve fund as required by applicable law. During the year 2023, the Company had a net profit from operations of 30,931,719 Baht. However, the Company needs to reserve profits for working capital and business investments., so the company will not pay dividends.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

As this agenda item was for acknowledgment the omission of dividend payments for the year 2023, there was no resolution to be adopted.

Agenda 4 To consideration and approval of Transferring share premium to Offset Accumulated Company Losses

The Chairman assigned Mr. Dusit Chongsutthanamanee, Vice Chairman to present information to the Meeting.

Vice Chairman presented to the meeting that the share premium has detail as below:

Statement	Amount (Baht)
Deficits as at 31 December 2023	(103,272,960)
Transfer share premium to compensate the deficits	103,272,960
Share premium	947,266,423

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

Company Secretary requested shareholders to adopt a resolution approving the transfer of share premium in the amount of 103,272,960 Baht to offset the accumulated losses of the Company.

The voting results were as follows:

Approved	153,051,902	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Abstained	0	Votes	Equivalent to	0.0000
Total	153,051,902	Votes	Equivalent to	100.0000

Page 9 / 14





The meeting's resolution: With the majority votes of the shareholders who were present at the meeting and casted their votes, the meeting passed the resolution approving the transfer of share premium in the amount of 103,272,960 Baht to offset the accumulated losses of the Company as proposed in all respects.

Agenda 5 To consider and approve the appointment of the directors those retired by rotation to re-elect the aforementioned to be the Company's director for another term.

The Chairman as member of the Nomination and Remuneration Committee presented information to the Meeting.

The member of the Nomination and Remuneration Committee informed that Article 22 of the Company's Articles of Association stipulates that 1/3 of the total number of directors shall retire from the company. The shareholders can re-appoint the directors who have completed their term for re-entry. Therefore, 1/3 of the total 5 directors of the Company are 2 people who must retire by rotation at the annual general meeting of shareholders every year. Therefore, it must be proposed to the shareholders to consider appointing directors to replace those who are due to retire by rotation, namely Mr. Dusit Chongsutthanamanee and Ms. Suwarin Konthong.

The Nomination and Remuneration Committee, excluding directors with conflict of interest, considered the 2 directors to have the necessary qualifications as per the Public Limited Companies Act B.E.2535 and relevant knowledge, including valuable experience that can help the operations of the Company. Hence, the Nomination and Remuneration Committee deemed it appropriate to propose the re-appointment of the Company's directors in place of the directors who are retired by rotation. The profile of the 2 directors shown on the attachment No.5.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

Company Secretary requested shareholders to adopt a resolution approving the appointment of the directors those retired by rotation to re-elect the aforementioned to be the Company's director for another term.



DOD Biotech Public Company Limited 111 Moo 2 Tumbol Thachin, Amphur Muang Samutsakhon Samutsakhon 74000

The voting results were as follows:

1. Mr. Dusit Chongsutthanamanee :

Approved	153,053,902	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Abstained	0	Votes	Equivalent to	0.0000
Total	153,053,902	Votes	Equivalent to	100.0000

2. Ms. Suwarin Konthong :

Approved	153,053,902	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Abstained	0	Votes	Equivalent to	0.0000
Total	153,053,902	Votes	Equivalent to	100.0000

The meeting's resolution: With the majority votes of the shareholders who attended the meeting and casted their votes, the meeting passed the resolutions re-electing the 2 candidates as Directors in replacement of the ones retiring by rotation as proposed in all respects.

Agenda 6 To approve the fixing of the director's remuneration for the year 2024

The Chairman assigned Mr. Dusit Chongsutthanamanee, Chairman of the Nomination and Remuneration Committee to present information to the Meeting.

Chairman of the Nomination and Remuneration Committee explained that the Board of Directors agreed with the regulation on the remuneration of the Company, proposed by the Nomination and Remuneration Committee. The regulation on remuneration considers duty, responsibility, achievement, and interest received from each director, and the financial amount in the year 2024 is limited is not exceeding Baht 5.0 million that amount is the same as last year from shareholders' approval.

For vote-counting of this agenda, the votes of directors who are stakeholders have no right to vote, with a total shareholding of 473,100 votes, which does not count as the base of votes in the vote-counting. In this agenda, a resolution must be passed with a vote of not less than two-thirds of the total number of votes of the shareholders attending the meeting according to the Public Act, Section 90.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

Page 11 / 14



Company Secretary requested shareholders to adopt a resolution approving the appointment of the director's remuneration for the year 2024.

The voting results were as follows:

Approved	152,580,802	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Abstained	0	Votes	Equivalent to	0.0000
Not entitled to vote	473,100	Votes		
Total	152,580,802	Votes	Equivalent to	100.0000

The meeting's resolution: With a majority of more than two-thirds of the votes of the shareholders who were present at the meeting, the meeting adopted a resolution approving the fixing of the director's remuneration for the year 2024 as proposed in all respects.

Agenda 7 To approve the appointment of the auditors and fixing the audit fee for the year 2024

The Chairman assigned Mr. Dusit Chongsutthanamanee, Chairman of Audit Committee, to present information to the Meeting.

The Chairman of the Audit Committee informed the meeting that the Audit Committee has a process for selecting auditors for the year 2024 and proposes to the Board of Directors for consideration and proposals to the shareholders' meeting for appointment.

1. Ms. Sumesa Tangyoosuk	Certified Public Accountant no. 7627
2. Mrs. Phoonnard Phaocharean	Certified Public Accountant no. 5238
3. Ms. Manee Rattanabunnakit	Certified Public Accountant no. 5313
4. Ms. Sineenart Jirachaikhuankhan	Certified Public Accountant no. 6287

From EY Office Co., Ltd. is the Company's accountant for the year 2024, with the Audit Committee's opinion that EY Office Co., Ltd. has a comprehensive network that is recognized in many countries. This will make the auditing standard of the company international and all 4 auditors, including EY Office Company Limited, have no relationship or transaction that may cause a conflict of interest. The audit fees proposed in 2024 are determined in the amount not exceeding Baht 2.5 million.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.



Company Secretary requested shareholders to adopt a resolution approving the appointment of the auditors and fixing the audit fee for the year 2024.

The voting results were as follows:

Approved	153,053,902	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Abstained	0	Votes	Equivalent to	0.0000
Total	153,053,902	Votes	Equivalent to	100.0000

The meeting's resolution: With the majority votes of the shareholders who were present at the meeting and casted their votes, the meeting passed the resolution approving appointment of the auditors and fixing the audit fee for the year 2024 as proposed in all respects.

Agenda 8 Other businesses (if any).

The Chairman assigned Miss Arachaporn Boonkerd, Company Secretary, to present information to the Meeting.

Company Secretary informed the meeting that Section 105 of the Public Limited Companies Act B.E. 2535 states that "the shareholders holding the aggregate number of shares of not less than one-third of the total number of shares sold may request the consideration at the meeting of other business in addition to that specified in the notice summoning the meeting" Therefore, there is an agenda 8 as stipulated by law.

Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

The Chairman thanked the shareholders for taking the time to attend the meeting and declared the meeting closed.

The meeting was closed at 16:00 hours.

Note: The voting scores reported in this meeting do not correspond to those announced in the meeting due to an increase in the number of shareholders during each agenda item.

Signed



----- Signature----- Chairman of The Meeting (Mrs. Arpaporn Kosolkul) Chairman

> Miss Arachaporn Boonkerd Secretary to the meeting/ Minute's recorder

> > Page 13 / 14